Successful Electroconvulsive Treatment of a Schizophrenic Patient Suffering from Severe Haemophilia A

Glaub, T.; Telek, B; Boda, Zoltán; Szabó, Sándor; Králl, G.; Rák, K.

doi:10.1055/s-0038-1650408

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, none of the patients developed intracranial hemorrhage. In hemophilia itself, Glaub et al 2 demonstrated that ECT could be performed without bleeding or other complications when patients with hemophilia A were pre-treated with factor VIII concentrates. Our report shows the safety of ECT for patients with hemophilia A when they are supplemented with coagulation factor VIII.…”

Section: Discussionmentioning

confidence: 99%

“…However, only one paper reports a demonstration of the safe usage of ECT in a patient with hemophilia. 2 Herein, we describe a second case of successful ECT for medication-resistant schizophrenia in a patient with severe hemophilia A.…”

Section: Introductionmentioning

confidence: 98%

“…The dose of Kogenate ® FS was determined to keep factor VIII activity at 30%–40% during ECT. The factor VIII activity target range was recommended by hematologists based on the report by Glaub et al 2 Since the patient’s mental state was impaired, written informed consent for the procedure was obtained from the patient’s family.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito¹,

Shioda²,

Nisijima³

et al. 2014

NDT

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) is used for medication-resistant and life-threatening mental disorders, and therefore it occupies an important position in psychiatric treatment. ECT reportedly increases intracranial pressure and is suspected of increasing the risk of intracranial hemorrhage, especially in patients with hemorrhagic diseases such as hemophilia. A decrease in or loss of blood coagulation factors, including factor VIII and factor IX, are found in hemophilia A and B, respectively. Psychiatrists may hesitate to perform ECT on patients with bleeding tendencies, such as in hemophilia. Here, we report the successful use of ECT on a neuroleptic-resistant patient with schizophrenia and severe hemophilia A. We performed ECT 16 times supplemented with coagulation factor VIII to prevent intracranial and systematic hemorrhage. We administered factor VIII concentrates to the patient to keep factor VIII activity at 30%–40% during ECT. The patient did not show bleeding or other complications during the ECT sessions. We suggest that pretreatment with factor VIII can help manage the increased risks of intracranial and systematic bleeding during ECT that is present in patients with hemophilia A. The present report supports the idea of performing ECT safely on patients with hemophilia A by administering factor VIII.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%